bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.
Article Date
June 16, 2025
This article is featured on another website.
Go to article
April 28, 2026
Clinical Research Consulting vs. FSP in Biotech and Pharma: Knowing When an FSP Is the Right Fit
Clinical Research Consulting vs. FSP: Choosing the Right Model for Biotech and Pharma Companies Biotech…
April 28, 2026
Clinical Research Consulting vs. FSP in Biotech and Pharma: Knowing When an FSP Is the Right Fit
Clinical Research Consulting vs. FSP: Choosing the Right Model for Biotech and Pharma Companies Biotech…